Literature DB >> 31731986

New Drugs for the Treatment of Tuberculosis.

Elisa H Ignatius1, Kelly E Dooley2.   

Abstract

Tuberculosis (TB) has now surpassed HIV as the leading infectious cause of death, and treatment success rates are declining. Multidrug-resistant TB, extensively drug-resistant TB, and even totally drug-resistant TB threaten to further destabilize disease control efforts. The second wave in TB drug development, which includes the diarylquinoline, bedaquiline, and the nitroimidazoles delamanid and pretomanid, may offer options for simpler, shorter, and potentially all-oral regimens to treat drug-resistant TB. The "third wave" of TB drug development includes numerous promising compounds, including less toxic versions of older drug classes and candidates with novel mechanisms of action.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bedaquiline; Delamanid; New drugs; Pharmacology; Pretomanid; Tuberculosis

Mesh：

Substances：

Year:  2019        PMID： 31731986      PMCID： PMC9178517          DOI： 10.1016/j.ccm.2019.08.001

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN： 0272-5231            Impact factor:   4.967


  100 in total

1.  Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.

Authors:  Andreas H Diacon; Rodney Dawson; Madeleine Hanekom; Kim Narunsky; Stefan J Maritz; Amour Venter; Peter R Donald; Christo van Niekerk; Karl Whitney; Doris J Rouse; Martino W Laurenzi; Ann M Ginsberg; Melvin K Spigelman
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

2.  Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.

Authors:  Zahoor Ahmad; Austin Minkowski; Charles A Peloquin; Kathy N Williams; Khisimuzi E Mdluli; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects.

Authors:  Ann M Ginsberg; Martino W Laurenzi; Doris J Rouse; Karl D Whitney; Melvin K Spigelman
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

4.  South Africa warns of emergence of "totally" drug-resistant tuberculosis.

Authors:  Anita Slomski
Journal:  JAMA       Date:  2013-03-20       Impact factor: 56.272

5.  Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

Authors:  Andreas H Diacon; Alexander Pym; Martin P Grobusch; Jorge M de los Rios; Eduardo Gotuzzo; Irina Vasilyeva; Vaira Leimane; Koen Andries; Nyasha Bakare; Tine De Marez; Myriam Haxaire-Theeuwes; Nacer Lounis; Paul Meyvisch; Els De Paepe; Rolf P G van Heeswijk; Brian Dannemann
Journal:  N Engl J Med       Date:  2014-08-21       Impact factor: 91.245

6.  Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.

Authors:  Kwok-Chiu Chang; Eric Chung-Ching Leung; Wing-Sze Law; Wai-Man Leung; Lai-Bun Tai; Shuk-Nor Lee; Fai-Man Lam; Chi-Hung Chau; Thomas Yun-Wing Mok; Wing-Wai Yew; Chi-Chiu Leung
Journal:  Eur Respir J       Date:  2018-06-14       Impact factor: 16.671

7.  Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).

Authors:  Andréanne Lupien; Anthony Vocat; Caroline Shi-Yan Foo; Emilyne Blattes; Jean-Yves Gillon; Vadim Makarov; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

8.  Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.

Authors:  Margreke J E Brill; Elin M Svensson; Mishal Pandie; Gary Maartens; Mats O Karlsson
Journal:  Int J Antimicrob Agents       Date:  2016-12-14       Impact factor: 5.283

9.  Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.

Authors:  Alexander S Pym; Andreas H Diacon; Shen-Jie Tang; Francesca Conradie; Manfred Danilovits; Charoen Chuchottaworn; Irina Vasilyeva; Koen Andries; Nyasha Bakare; Tine De Marez; Myriam Haxaire-Theeuwes; Nacer Lounis; Paul Meyvisch; Ben Van Baelen; Rolf P G van Heeswijk; Brian Dannemann
Journal:  Eur Respir J       Date:  2015-12-02       Impact factor: 16.671

10.  Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Authors:  Andrey Maryandyshev; Emanuele Pontali; Simon Tiberi; Onno Akkerman; Shashank Ganatra; Tsetan Dorji Sadutshang; Jan-Willem Alffenaar; Rohit Amale; Jai Mullerpattan; Sonam Topgyal; Zarir Farokh Udwadia; Rosella Centis; Lia D'Ambrosio; Giovanni Sotgiu; Giovanni Battista Migliori
Journal:  Emerg Infect Dis       Date:  2017-10-17       Impact factor: 6.883
View more
  8 in total

1.  2019: A Banner Year for Tuberculosis Research.

Authors:  Robert W Eisinger; Alan C Embry; Sarah W Read; Anthony S Fauci
Journal:  J Infect Dis       Date:  2020-11-09       Impact factor: 5.226

Review 2.  Ribosome hibernation: a new molecular framework for targeting nonreplicating persisters of mycobacteria.

Authors:  Yunlong Li; Manjuli R Sharma; Ravi K Koripella; Nilesh K Banavali; Rajendra K Agrawal; Anil K Ojha
Journal:  Microbiology (Reading)       Date:  2021-02       Impact factor: 2.777

Review 3.  Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment.

Authors:  Filia Stephanie; Mutiara Saragih; Usman Sumo Friend Tambunan
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

Review 4.  Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment.

Authors:  Radha Gopalaswamy; Sivakumar Shanmugam; Rajesh Mondal; Selvakumar Subbian
Journal:  J Biomed Sci       Date:  2020-06-17       Impact factor: 8.410

5.  Replacement of S14 Protein in Ribosomes of Zinc-Starved Mycobacteria Reduces Spectinamide Sensitivity.

Authors:  Yunlong Li; Ravi K Koripella; Manjuli R Sharma; Richard E Lee; Rajendra K Agrawal; Anil K Ojha
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

6.  Total Synthesis of the Antimycobacterial Natural Product Chlorflavonin and Analogs via a Late-Stage Ruthenium(II)-Catalyzed ortho-C(sp2)-H-Hydroxylation.

Authors:  Alexander Berger; Talea Knak; Anna-Lene Kiffe-Delf; Korana Mudrovcic; Vinayak Singh; Mathew Njoroge; Bjoern B Burckhardt; Mohanraj Gopalswamy; Beate Lungerich; Lutz Ackermann; Holger Gohlke; Kelly Chibale; Rainer Kalscheuer; Thomas Kurz
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-10

Review 7.  Pretomanid for tuberculosis treatment: an update for clinical purposes.

Authors:  Sara Occhineri; Tommaso Matucci; Laura Rindi; Giusy Tiseo; Marco Falcone; Niccolò Riccardi; Giorgio Besozzi
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-09-09

8.  Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832.

Authors:  Gregory T Robertson; Michelle E Ramey; Lisa M Massoudi; Claire L Carter; Matt Zimmerman; Firat Kaya; Barbara G Graham; Veronica Gruppo; Courtney Hastings; Lisa K Woolhiser; Dashick W L Scott; Bryce C Asay; Franceen Eshun-Wilson; Ekaterina Maidj; Brendan K Podell; Joshua J Vásquez; Mike A Lyons; Véronique Dartois; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.